WO2002060405A1 - Composition dermatologique veterinaire contenant une base sphingoide et/ou un derive de base sphingoide - Google Patents

Composition dermatologique veterinaire contenant une base sphingoide et/ou un derive de base sphingoide Download PDF

Info

Publication number
WO2002060405A1
WO2002060405A1 PCT/EP2001/001019 EP0101019W WO02060405A1 WO 2002060405 A1 WO2002060405 A1 WO 2002060405A1 EP 0101019 W EP0101019 W EP 0101019W WO 02060405 A1 WO02060405 A1 WO 02060405A1
Authority
WO
WIPO (PCT)
Prior art keywords
veterinary
acid
composition
sphingoid base
active compound
Prior art date
Application number
PCT/EP2001/001019
Other languages
English (en)
Other versions
WO2002060405A8 (fr
Inventor
Jean-Claude Allart
Jean-Marie Lefevre
Jacques Peyrot
Original Assignee
Cosmoferm B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8164268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002060405(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cosmoferm B.V. filed Critical Cosmoferm B.V.
Priority to PCT/EP2001/001019 priority Critical patent/WO2002060405A1/fr
Priority to CA2436414A priority patent/CA2436414C/fr
Priority to AT02710835T priority patent/ATE350106T1/de
Priority to PT02710835T priority patent/PT1355626E/pt
Priority to DK02710835T priority patent/DK1355626T3/da
Priority to US10/470,299 priority patent/US8246972B2/en
Priority to DE60217292T priority patent/DE60217292T2/de
Priority to PCT/EP2002/001120 priority patent/WO2002060406A2/fr
Priority to EP02710835A priority patent/EP1355626B1/fr
Priority to ES02710835T priority patent/ES2275846T3/es
Publication of WO2002060405A1 publication Critical patent/WO2002060405A1/fr
Publication of WO2002060405A8 publication Critical patent/WO2002060405A8/fr
Priority to US13/554,637 priority patent/US9198855B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a veterinary dermatologic composition.
  • the skin of a living being constitutes a barrier to the environment which is capable of adapting itself to varying environmental conditions. Besides forming a structural barrier to the environment, the skin plays an important physiological role in that it provides physical protection, assists in the thermal regulation of the organism and has a metabolic, sensorial and storage function.
  • the physical barrier function of the skin is mainly provided by the outermost lipid layer or stratum corneum.
  • the ceramides present in the stratum corneum which mainly result from enzymatic deglycosylation of cerebrosides, provide protective properties and form a permeable lipid filter, in particular a hydrophobic barrier, towards the environment.
  • Jthe skin also provides a chemical barrier function in that the skin surface is colonised by a wide variety of micro-organisms that assist in maintaining a natural equilibrium of the skin.
  • this natural equilibrium may get disturbed, involve an uncontrollable outgrowth of certain microorganisms within the skin microflora and the consequential impaired lipid barrier function and dermatologic infections.
  • animals in particular furry animals, domestic animals as well as farm animals, the number of cutaneous infections where over-populations of micro-organisms intervene, is severely increasing.
  • sphingoid base containing formulations show growth-inhibitory activity against gram- negative as well as against gram-positive bacteria on the human skin, when present in a concentration of at least 0.005 wt. %.
  • Antimicrobial activity of sphingoid bases has been found against bacteria, yeasts and fungi.
  • Typical applications include treatment of acne, dandruff, mycoses, i.e. cosmetic and/or dermatological applications on human skin and hair.
  • FR-A-2.679.770 dispersions of a ceramide and/or glycoceramide in specific surface active agents are disclosed for use as e.g. a shampoo or rinsing agent with which disentangling of hair may be facilitated.
  • the surface active agents disclosed include quaternary ammonium salts and halogenated tetra-alkyl ammonium compounds.
  • the veterinary dermatological composition contains as an active compound an amount of a sphingoid base, a sphingoid base derivative, a salt of a sphingoid base or a mixture of two or more of these compounds.
  • the application field of the composition may vary from a preventive point of view, for example a hygienic composition which assists in restoring the barrier function of the skin and regulates the microbial population of the skin, to a curative point of view in an advanced dermatologic product, a veterinary medicament or as a complementary product to other medicaments.
  • the animal skin differs from the human skin mainly by the presence of a dense coat of hair which plays an essential role in the protection of the homeostatic equilibrium.
  • compositions of this invention are not only capable of showing anti-microbial and anti-fungal activity to a fur coated skin, but also that they are capable of preventing or regulating microbial over-population of the animal skin and fur.
  • the effect of the active compound of this invention can be explained by two synergistic effects. As the presence of a dense coat of hair on the animal skin constitutes a focus for the growth of microorganisms, there is an increased risk to the occurrence of infections.
  • the composition of this invention interferes herein in that due to its antimicrobial properties, the overpopulation of micro-organisms not only on the animal skin but also in the animal hair or fur may be counteracted.
  • a first effect is thus to be found in the fact that with the composition of this invention, the ecoflora of the animal fur and thus the risk to the occurrence of infections, can be controlled.
  • the active compound of this invention has been found capable of enhancing recovery of the animal skin when irritated, inflammated or in case of lesions, and of improving vertical cohesion of skin cells as a result of which skin irritation and the tendency to scratching are counteracted.
  • the composition thus shows a dual action, with which both the micro-organism population of the skin and fur may be controlled and the recovery capacity of the skin may be enhanced and in the end the over-all health of the animal will be improved. Up to now, skin and fur problems with animals were largely ignored.
  • the type of sphingoid base used in the composition of this invention is not critical to the invention.
  • the sphingoid base is preferably selected from the group of sphingosine, sphinganine and phytosphingosine, although phytosphingosine is preferred.
  • the sphingoid base used in the veterinary composition of this invention may be obtained from any suitable source, it may for example originate from a natural source, but preferably it is synthesised through a chemical process or fermentation process. To allow controlling the price of the veterinary composition, it is desirable that a sphingosine is used which is obtainable in reasonable amounts at commercially feasible costs. Chemically synthesised sphingoid base appears to be somewhat expensive as it is difficult to obtain the desired stereochemical configuration. Animal or vegetal sphingoid base can be obtained from extraction followed by purification of animal and vegetal tissue. Besides the fact that this is an expensive production route, animal sources are believed to be somewhat unsafe due to the regular occurrence of infections that are dangerous to man kind.
  • the sphingoid. base used in the present invention is preferably obtained from a microbial fermentation process. More preferably it is obtained from a yeast, in particular Pichia cifieri as the thus obtainable phytosphingosine has been found to resemble animal skin in the best way.
  • phytosphingosine is used as the sphingoid base which is obtained from Pichia c/fer/ ⁇ -derived tetra-acetyl-phytosphingosine (TAPS), through deacetylation.
  • the deacetylation reaction may be a chemical reaction, for example an alkali catalysed hydrolysis in the presence of KOH, or may be an enzymatic reaction.
  • a phytosphingosine with a high purity it may be desirably to subject the phytosphingosine resulting from the hydrolysis reaction to a purification step.
  • a purification step Thereto any purification method known to the man skilled in the art may be used.
  • sphingoid base derivatives include N-lactyloyl-phytosphingosine, N-salicyloyl-phytosphingosine, N- retinoyl-phytosphingosine, i.e. compounds which are N-substituted.
  • the anion of the salt may be derived from any suitable acid, i.e. those acids which upon mixing with the sphingoid base in a suitable solid produce a slat with an improved water solubility.
  • suitable acid i.e. those acids which upon mixing with the sphingoid base in a suitable solid produce a slat with an improved water solubility.
  • the acids which itself are effective when applied to fur or skin are preferred.
  • Preferred salts of the sphingoid base for use in the composition of this invention are the salts obtainable with those acids which upon mixing with the above mentioned sphingoid base in a suitable solvent, produce a, salt with an increased water solubility as compared to the water solubility of the sphingoid base as such.
  • the salts of phytosphingosine are preferred for better solubility and better bio- aivalability.
  • the acid is a hydrophilic acid capable of delivering the sphingoid base salt to the water phase of the veterinary composition.
  • Suitable hydrophilic acids include ⁇ -hydroxy alkanoic acid, a ⁇ -hydroxy alkanoic acid, an , ⁇ -dihydroxy alkanoid acid, an alkanedioic acid or a mineral acid.
  • preferred hydrophylic organic acids are lactic acid, glycolic acid, malic acid, pyruvic acid, succinic acid, fumaric acid, ascorbic acid, gluconic acid and/or pyroglutamic acid.
  • preferred mineral acids are hydrochloric acid, nitric acid and/or phosphoric acid.
  • the acid is a lipophilic organic acid to allow increasing both the efficacy of the lipophilic acid and the sphingoid base in the sphingoid base salt.
  • the sphingoid base salts will be prepared prior to their inclusion in the veterinary composition, as the inclusion in the veterinary composition of the sphingoid base as such and one or more of the above described acids will in general not result in an increased efficacy.
  • a preferred process for preparing the sphingoid base salts of this invention is described in WO 00/53568 which is here incorporated by reference.
  • an effective doses of a veterinary composition will usually contain 1-500 mg of the active sphingoid base compound.
  • the posology will usually be adapted to the phenomenon to be treated and the characteristics of the animal, e.g. type of animal, animal weight, age etc. In case of animals with a weight between approximately 5-50 kg such as for example domestic animals, usually two administrations per day will suffice when treating a disorder. For preventive treatment purposes one or a few administrations per week will most often be sufficient.
  • the frequency and dose may however be adapted to the specific type of animal.
  • Preferred concentrations of the active compound in the veterinary dermatological composition of this invention preferably range from 0.01-20 wt. % of the active compound.
  • the preferred concentration will usually be adapted to the type of application envisaged. More preferred concentrations may vary from 0.02 wt% to 10 wt. %, or 0.5- 5 wt. %.
  • Compositions intended for treating disorders will typically contain a higher amount of active compound than compositions intended for preventive use, e.g. normalisation of the flora of the fur and/or skin.
  • Compositions intended for regulating the desquamative condition or controlling sur-populations of micro-organisms or fungicides will most often contain 0.05-5 wt. % of the veterinary composition of this invention.
  • the veterinary composition of this invention may contain one or more compounds capable of improving the targeting to the location to be treated or the efficacy or having complementary activity to the active compounds of this invention.
  • examples of such compounds include (pseudo-) ceramides, preferably skin-identical ceramides, alpha-hydroxy acids for example lactic acid, citric acid, glycolic acid, beta-hydroxy acids for example salicylic acid, and derivatives of the afore mentioned hydroxy-acids, cytokines, anti inflammatory steroids and non-steroids, vitamine A, C, D, E, PP, biotine and B-type vitamines, hormones, benzoyl peroxide, various emolients, ureum, reductants, anti moth agents, antibiotics, anti-fungal agents, disinfectants and any other compounds with complementary activity known to the man skilled in the art.
  • the veterinary composition of this invention may further comprise an amount of one or more suitable adjuvants and/or formulation additives to render the composition suitable for application in the selected mode of administration of the veterinary composition, to assist in delivering the active compound to the required site, if so desired assist in dispersing the active compound over the complete epidermal surface and to allow the active compound to be maintained in an active condition for a period sufficiently long to prevent repetition of the distortion.
  • the veterinary compositions of this invention may contain one or more solvents, preferably water, an emollient for example a fat or an oil, or emulsions in which a mixture of water and fat or oil are used as solvent.
  • suitable adjuvants include amongst others known to the man skilled in the art, gelling agents, softening agents, emulsifying agents, surfactants, preservatives.
  • the surfactant for use with the veterinary composition of this invention is preferably selected from the group of ionic surfactants, anionic and/or cationic surfactants, and non-ionic surfactants.
  • the surfactant is selected from the group of betaines, ethoxylated sorbitan esters for example Tween 80, laureth sulphate or glycol distearate for example Texapon® or Sinnoflor ®.
  • the concentration of the surfactant will mostly vary from 0.01-10 wt. %, preferably from 0.1-5 wt. % or 0.5-2.5 wt. %.
  • Suitable gelling agents include polyacrylamides for example Carbopol ®, acryalte/acrylic acid compolymers for example Aculyn ®, acrylamide/acrylamido acid propane sulfite, cellulose derivatives, e.g. hydroxypropylcellulose and Klucel ®, vegetal muco- polysaccharides, waxes e.g. bee wax, natural gums e.g. xanthane gum.
  • emulsifying agents are those known to the man skilled in the art of veterinary products, for example sorbitan ester polysorbate, sorbitan stearate or laurate, stearic acid derivatives, propylene glycol stearate, polyethylene glycol steareth, a steareth or a ceteareth.
  • the emulsion is preferably a submicron emulsion the particle size of which is preferably between 50-200 ⁇ m.
  • Such emulsions may be applied in the usual manner, for example by spraying, aerosol.
  • Suitable softening agents include fatty alcohols or esters, isostearylic alcohol based products, sorbitol-polysaccharides for example Soothex ®, Rhamnosoft ®.
  • compositions of this invention may be applied in the form of a shampoo, foaming baths, spray, spot on, lotion, gels, emulsion, or other forms of application known to the man skilled in the art may also be used.
  • a spray will mostly be used in curative application, wheras a shampoo mostly will have a cleaning and preventive function and a lotion is especially suitable for cleaning of exsudative lesions and ensures a major antiseptic action without distorting the microflora of the fur.
  • the composition of this invention may contain one or more preservatives, the presence thereof may be omitted without this adversely affecting the stability of the composition. It is thus possible to prepare veterinary dermatologic compositions which are free of purposely added preservatives.
  • preservatives include methyl p-hydroxy-benzoate (methylparaben), propyl p-hydroxy-benzoate (propylparaben), Hinokitiol ®.
  • phytosphingosin shows anti-microbial activity against specific types of animal staphylocoques. It has been surprisingly found that the multiplication of Staphylococcus Intermedius cultures may be partly inhibited by administering 5 ppm of phytosphingosine or its hydrochloric acid salt and completely inhibited by administering 10 ppm of phytosphingosine or its hydrochloric acid salt. Experiments were carried out using doses of 0, 5, 10, 25, 50 and 100 ppm of phytosphingosine and its hydrochloric acid salt on Staphylococcus Intermedius in usual culture environment without solubilising agent.
  • the experiments have shown that the veterinary composition of this invention allows to simultaneously assist in curing inflammatory phenomena as well as solving primitive or secondary keratinisation problems. These effects are obviated by for example an over-all improvement of the quality of the fur, the smell, pruritus and desquamation.
  • a comparative study has been carried out to a group of seven dogs which showed a pathological fur: 4 dogs with DAPP, (atopic dermatitis) due to flee bites, one of which is associated with chronic seborreic dermatitis, two dogs showed atopi and one dog showed seborrhea. All dogs were treated with the composition of this invention in the shape of a foam, once a day for a period of 3 days, followed by two applications per week for three weeks.
  • the composition of this invention When applied to the whole epidermal surface of the animal, the composition of this invention showed prolongued activity, thus allowing to prevent the occurrence of consequential distortions with the animal as well as distortions resulting from stress implied with the animal. Besides this, the veterinary compositions of this invention appear to show improved drying properties, easy to apply, provide excellent cleaning properties and excellent after - treatment properties.
  • the above described experiments have shown that the veterinary composition of this invention can be successfully used in hygienic products as well as in veterinary medicine, in particular with cats and dogs, for treating all inflammatory pathologies related to stress, parasitoses, dermatoses, atopic dermatitis, superinfection folliculites, modifications of the flora, contact eczema.
  • Shampoo or foaming bases containing the veterinary composition of this invention proved to be particularly suitable for preventing and correcting cutaneous problems associated with a proliferation of Malassezia pachydermatis or Staphylococcus intermedius.
  • Emulsions, alcoholic lotions or sub-micronic emulsions are suitable for preventing fungal affections.
  • When treating chronical superficial folliculites of a dog, when preventing of fungal affections preferably use is made of a gel or a micellar lotion which is adapted to cleaning exsudative lesions. Dermatoses or superinfections involved by Staphylococcus intermedius can be successfully treated with a cream.
  • a sub-micron lotion for spraying was prepared with the following composition (amounts given in parts by weight): phytosphingosine 0.20 isodecyl isononanoate 15.00 octyldodecanole 10.00 diethylhexylcyclohexane 5.00 squalane 5.00 butylene glycol 3.00
  • a gel for topical application was prepared with the following composition (given in parts by weight)
  • composition of the ⁇ el base gel 45.00 ethanol 96° 27.30 cyclomethicone 11.50 alkylene lactate C12-C13 13.50 isostearyl alcohol (Soothex ®) 2.50 phytosphingosine 0.20
  • An emulsion for a foaming bases was prepared as known to the man skilled in the art, having the following composition (amounts given in parts by weight):
  • Phytosphingosine hydrochloric acid 0.25 surfactant (Texapon ®) 64.00 cyclomethicone 2.50 a ⁇ rylate copolymer 6.50 triethanolamine 1.10 ethanol 96° 1.00 softening agent 4.50 preservative 0.20 water up to 100
  • the dermatological composition of this invention is adapted for use in veterinary products and allows re-establishing of the animal ecoflora, preventing, correcting and treating of cutnaeous phenomena with animals, which are related to problems occurring in the ecoflora, for example microbial or fungal surpopulation, or problems occurring in the pathologic development of a specific micro-organism.
  • the dermatological composition of this invention in particular allows preventing and/or correcting inflammations related to specific parasitoss and dermatoses for example eczema, or originating from varying aggressions such as stress.
  • the dermatologic composition of this invention is also suitable for use in the preparation of a veterinary medicament when treating inflammations which may result from varying aggressions, for example from stress or be related to specific parasitoses and dermatoses.
  • compositions of this invention may be used in a more general manner to ensure regulation of the desquamative status, to control microbial and fungal surpopulations.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne une composition dermatologique vétérinaire adaptée à une application locale, la composition contenant en tant que composé actif une dose d'une base sphingoïde, un dérivé de base sphingoïde ou un mélange de deux de ces composés ou davantage.
PCT/EP2001/001019 2001-01-29 2001-01-29 Composition dermatologique veterinaire contenant une base sphingoide et/ou un derive de base sphingoide WO2002060405A1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
PCT/EP2001/001019 WO2002060405A1 (fr) 2001-01-29 2001-01-29 Composition dermatologique veterinaire contenant une base sphingoide et/ou un derive de base sphingoide
ES02710835T ES2275846T3 (es) 2001-01-29 2002-01-29 Composicion dermatologica veterinaria.
DK02710835T DK1355626T3 (da) 2001-01-29 2002-01-29 Veterinær, dermatologisk sammensætning
AT02710835T ATE350106T1 (de) 2001-01-29 2002-01-29 Veterinärmedizinische dermatologische zusammensetzung
PT02710835T PT1355626E (pt) 2001-01-29 2002-01-29 Composição dermatológica veterinária
CA2436414A CA2436414C (fr) 2001-01-29 2002-01-29 Composition a usage dermatologique et veterinaire
US10/470,299 US8246972B2 (en) 2001-01-29 2002-01-29 Veterinary dermatologic composition
DE60217292T DE60217292T2 (de) 2001-01-29 2002-01-29 Veterinärmedizinische dermatologische zusammensetzung
PCT/EP2002/001120 WO2002060406A2 (fr) 2001-01-29 2002-01-29 Composition a usage dermatologique et veterinaire
EP02710835A EP1355626B1 (fr) 2001-01-29 2002-01-29 Composition a usage dermatologique et veterinaire
US13/554,637 US9198855B2 (en) 2001-01-29 2012-07-20 Veterinary dermatologic composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2001/001019 WO2002060405A1 (fr) 2001-01-29 2001-01-29 Composition dermatologique veterinaire contenant une base sphingoide et/ou un derive de base sphingoide

Publications (2)

Publication Number Publication Date
WO2002060405A1 true WO2002060405A1 (fr) 2002-08-08
WO2002060405A8 WO2002060405A8 (fr) 2003-10-30

Family

ID=8164268

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2001/001019 WO2002060405A1 (fr) 2001-01-29 2001-01-29 Composition dermatologique veterinaire contenant une base sphingoide et/ou un derive de base sphingoide
PCT/EP2002/001120 WO2002060406A2 (fr) 2001-01-29 2002-01-29 Composition a usage dermatologique et veterinaire

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/001120 WO2002060406A2 (fr) 2001-01-29 2002-01-29 Composition a usage dermatologique et veterinaire

Country Status (9)

Country Link
US (2) US8246972B2 (fr)
EP (1) EP1355626B1 (fr)
AT (1) ATE350106T1 (fr)
CA (1) CA2436414C (fr)
DE (1) DE60217292T2 (fr)
DK (1) DK1355626T3 (fr)
ES (1) ES2275846T3 (fr)
PT (1) PT1355626E (fr)
WO (2) WO2002060405A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045365A2 (fr) * 2001-11-21 2003-06-05 Universita Degli Studi Di Roma 'tor Vergata' Composes immunoregulateurs
US10092643B2 (en) 2005-06-30 2018-10-09 Kherion Technology Limited Prophylactic and immunomodulatory compositions and uses
US11000458B2 (en) 2017-03-27 2021-05-11 Evonik Operations Gmbh Method and product for producing formulations containing ceramide

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539125A4 (fr) * 2002-08-14 2005-09-14 Kim Tae Yoon Composition comprenant des derives de phytosphingosine utiles dans l'induction de l'apoptose
DE102011109546A1 (de) * 2011-08-03 2013-02-07 Evonik Goldschmidt Gmbh Verwendung von Sphinganin zur Verbesserung des visuellen Erscheinungsbildes von Haut und Haar
KR101342851B1 (ko) 2011-12-07 2013-12-17 가톨릭대학교 산학협력단 신규한 피토스핑고신 유도체 및 이를 포함하는 염증성 피부질환, 자가면역질환 및 피부과다각화증질환 예방 및 치료용 조성물
KR101288776B1 (ko) * 2011-12-07 2013-07-22 가톨릭대학교 산학협력단 신규한 피토스핑고신 유도체 및 이를 포함하는 염증성 피부질환과 피부과다각화증질환 예방 및 개선용 화장료 조성물
EP3259990A1 (fr) * 2016-06-20 2017-12-27 Ceva Sante Animale Procédés pour lutter contre les ectoparasites chez les mammifères non humaines

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0381514A2 (fr) * 1989-02-03 1990-08-08 The Biomembrane Institute Utilisation de la N-méthyl-sphingosine comme inhibiteur de la croissance cellulaire
WO1995003028A1 (fr) * 1993-07-23 1995-02-02 Morris Herstein Composition cosmetique stimulant le renouvellement de la peau, avec effet prolonge d'elimination de l'irritation
DE19602111A1 (de) * 1996-01-22 1997-07-24 Beiersdorf Ag Gegen Bakterien, Mycota, Parasiten, Protozoen und Viren wirksame Zusammensetzungen auf der Basis von Squalen, Sphingolipiden und Fettsäuren
DE19602108A1 (de) * 1996-01-22 1997-07-24 Beiersdorf Ag Gegen Bakterien, Parasiten, Protozoen, Mycota und Viren wirksame Substanzen
FR2747307A1 (fr) * 1996-04-11 1997-10-17 Ravi Shrivastava Application a titre de medicament des ceramides et compositions notamment pharmaceutiques les renfermant
WO1998049999A2 (fr) * 1997-05-02 1998-11-12 Gist-Brocades B.V. Compositions antimicrobiennes destinees a un usage topique
US5882665A (en) * 1997-11-18 1999-03-16 Elizabeth Arden Co., Division Of Conopco, Inc. Phytosphingosine salicylates in cosmetic compositions
WO2000053568A1 (fr) * 1999-03-09 2000-09-14 Cosmoferm B.V. Derives a base sphingoide et leurs utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306383B1 (en) * 1998-09-16 2001-10-23 Wilson T Crandall Method for topical treatment of scars with protein kinase C inhibitors
US6361806B1 (en) * 2000-02-23 2002-03-26 Michael P. Allen Composition for and method of topical administration to effect changes in subcutaneous adipose tissue

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0381514A2 (fr) * 1989-02-03 1990-08-08 The Biomembrane Institute Utilisation de la N-méthyl-sphingosine comme inhibiteur de la croissance cellulaire
WO1995003028A1 (fr) * 1993-07-23 1995-02-02 Morris Herstein Composition cosmetique stimulant le renouvellement de la peau, avec effet prolonge d'elimination de l'irritation
DE19602111A1 (de) * 1996-01-22 1997-07-24 Beiersdorf Ag Gegen Bakterien, Mycota, Parasiten, Protozoen und Viren wirksame Zusammensetzungen auf der Basis von Squalen, Sphingolipiden und Fettsäuren
DE19602108A1 (de) * 1996-01-22 1997-07-24 Beiersdorf Ag Gegen Bakterien, Parasiten, Protozoen, Mycota und Viren wirksame Substanzen
FR2747307A1 (fr) * 1996-04-11 1997-10-17 Ravi Shrivastava Application a titre de medicament des ceramides et compositions notamment pharmaceutiques les renfermant
WO1998049999A2 (fr) * 1997-05-02 1998-11-12 Gist-Brocades B.V. Compositions antimicrobiennes destinees a un usage topique
US5882665A (en) * 1997-11-18 1999-03-16 Elizabeth Arden Co., Division Of Conopco, Inc. Phytosphingosine salicylates in cosmetic compositions
WO2000053568A1 (fr) * 1999-03-09 2000-09-14 Cosmoferm B.V. Derives a base sphingoide et leurs utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIBEL, D. J. ET AL: "Topical sphingolipids in antisepsis and antifungal therapy.", CLINICAL AND EXPERIMENTAL DERMATOLOGY, (1995) VOL. 20, NO. 5, PP. 395-400., XP001015736 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045365A2 (fr) * 2001-11-21 2003-06-05 Universita Degli Studi Di Roma 'tor Vergata' Composes immunoregulateurs
WO2003045365A3 (fr) * 2001-11-21 2004-03-25 Univ Roma Composes immunoregulateurs
US9078907B2 (en) 2001-11-21 2015-07-14 Universita Degli Studi Di Roma “Tor Vergata” Immunoregulator compounds
US10092643B2 (en) 2005-06-30 2018-10-09 Kherion Technology Limited Prophylactic and immunomodulatory compositions and uses
US11000458B2 (en) 2017-03-27 2021-05-11 Evonik Operations Gmbh Method and product for producing formulations containing ceramide

Also Published As

Publication number Publication date
US20050037035A1 (en) 2005-02-17
WO2002060405A8 (fr) 2003-10-30
ES2275846T3 (es) 2007-06-16
EP1355626B1 (fr) 2007-01-03
EP1355626A2 (fr) 2003-10-29
ATE350106T1 (de) 2007-01-15
PT1355626E (pt) 2007-03-30
WO2002060406A3 (fr) 2003-02-20
WO2002060406A8 (fr) 2003-10-30
US9198855B2 (en) 2015-12-01
US20130190401A1 (en) 2013-07-25
DK1355626T3 (da) 2007-05-07
DE60217292T2 (de) 2007-05-31
CA2436414A1 (fr) 2002-08-08
US8246972B2 (en) 2012-08-21
WO2002060406A2 (fr) 2002-08-08
CA2436414C (fr) 2010-09-28
DE60217292D1 (de) 2007-02-15

Similar Documents

Publication Publication Date Title
US9198855B2 (en) Veterinary dermatologic composition
EP2348832B1 (fr) Système de conservation pour formulations topiques thérapeutiques à base d'émulsion
JP4418976B2 (ja) 防腐殺菌剤及び化粧料組成物
JP7148994B2 (ja) ビスホスホシンゲル製剤及びその使用
EP0914075B1 (fr) Compositions antimicrobiennes destinees a un usage topique
US20230247991A1 (en) Antimicrobial mixture containing 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one and an organic acid compound, and cosmetic composition containing same
DE60212842T2 (de) Dermatologische zusammensetzungen, die nikotinsäure oder nikotinsäureamid und sphingoid-base enthalten
KR101788179B1 (ko) 방부력이 우수한 저자극성 피부 외용제 조성물
US20040072789A1 (en) Veterinary composition for the topical treatment of traumatized or inflamed skin
EP3638219B1 (fr) Composition comprenant le terpinen-4-ol pour le traitement de la démodécie
FR2820037A1 (fr) Composition dermatologique a usage veterinaire comprenant une base sphingoide
JP2009167139A (ja) 外用組成物
FR2820038A1 (fr) Composition dermatologique a usage veterinaire comprenant une base sphingoide
TWI474841B (zh) 乳劑基治療局部製劑的保存系統
CN118159264A (zh) 抗真菌组合物
JP4294637B2 (ja) 防腐殺菌剤並びに該防腐殺菌剤を配合した化粧品、医薬品又は食品

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WA Withdrawal of international application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 32/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION.

Free format text: IN PCT GAZETTE 32/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION.

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642